Testosterone to Dihydrotestosterone Ratio as a New Biomarker for an Adverse Metabolic Phenotype in the Polycystic Ovary Syndrome

被引:84
|
作者
Muenzker, J. [1 ]
Hofer, D. [1 ]
Trummer, C. [1 ]
Ulbing, M. [1 ]
Harger, A. [1 ]
Pieber, T. [1 ]
Owen, L. [2 ]
Keevil, B. [2 ]
Brabant, G. [3 ,4 ]
Lerchbaum, E. [1 ]
Obermayer-Pietsch, B. [1 ]
机构
[1] Med Univ Graz, Dept Internal Med, Div Endocrinol & Metab, A-8036 Graz, Austria
[2] Univ S Manchester Hosp, Manchester Acad Hlth Sci Ctr, Dept Clin Chem, Manchester M23 9LT, Lancs, England
[3] Univ Manchester, The Christie, Dept Endocrinol, Manchester M20 4BX, Lancs, England
[4] Med Univ Lubeck, Expt & Clin Endocrinol, Med Clin 1, D-23538 Lubeck, Germany
基金
奥地利科学基金会;
关键词
SERUM TESTOSTERONE; MASS-SPECTROMETRY; SYNDROME PCOS; WOMEN; RISK; HYPERANDROGENEMIA; IMMUNOASSAY; ENDOCRINE; OBESITY; UTILITY;
D O I
10.1210/jc.2014-2523
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Polycystic ovary syndrome (PCOS) is a heterogeneous disease with many different aspects, including hyperandrogenism and metabolic disturbances. Clinical phenotypes show different patterns of steroid hormones that have been investigated to some extent. Objective: This study intended to determine the role of the testosterone (TT) to dihydrotestosterone (DHT) ratio (TT/DHT ratio) in PCOS patients and to further assess the correlation of this ratio with hormonal, anthropometric, and metabolic parameters. Design and Setting: Serum samples of 275 premenopausal PCOS patients fulfilling Rotterdam criteria and 35 BMI-matched, premenopausal, healthy controls were analyzed for testosterone, DHT, dehydroepiandrosterone (DHEA), and androstenedione using liquid chromatography/mass spectrometry. Main Outcome Measures: We measured total levels of testosterone and DHT and calculated un-bound hormone levels as well as the ratio of testosterone to DHT. Further, impaired glucose tolerance, basal and stimulated serum insulin levels, metabolic syndrome and insulin resistance according to the homeostatic model assessment (HOMA-IR) were assessed. Results: PCOS patients showed significantly higher levels of TT (P < .001), free testosterone (P < .001), and freeDHT(P < .001) compared to healthy controls. The TT/DHT ratio was significantly higher in PCOS patients (P < .001). No difference was found for total DHT levels (P < .072). In PCOS patients alone, the TT/DHT ratio was significantly higher in obese patients (P < .001) and patients with metabolic syndrome (P < .001), impaired glucose tolerance (IGT) (P < .001) or insulin resistance (P < .001). Significant correlations of the TT/DHT ratio with various adverse anthropometric, hormonal, lipid and liver parameters and parameters of glucose metabolism were found. Conclusion: Our data provide evidence for a strong link between a high TT/DHT ratio and an adverse metabolic phenotype in PCOS patients. This correlation was only found in PCOS patients, suggesting the TT/DHT ratio to be a new biomarker for an adverse metabolic phenotype in PCOS patients.
引用
收藏
页码:653 / 660
页数:8
相关论文
共 50 条
  • [1] Increased Ratio of Total Testosterone to Dihydrotestosterone May Predict an Adverse Metabolic Outcome in Polycystic Ovary Syndrome
    Shah, Sukanti
    Banu, Hurjahan
    Sultana, Tania
    Akhtar, Nazma
    Begum, Afroza
    Zamila, Begum Moriom
    Fariduddin, Md
    Abul Hasanat, Muhammad
    JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2019, 9 (06) : 186 - 192
  • [2] Hyperandrogenemia in Polycystic Ovary Syndrome: Exploration of the Role of Free Testosterone and Androstenedione in Metabolic Phenotype
    Lerchbaum, Elisabeth
    Schwetz, Verena
    Rabe, Thomas
    Giuliani, Albrecht
    Obermayer-Pietsch, Barbara
    PLOS ONE, 2014, 9 (10):
  • [3] Role of androgen ratios in the prediction of the metabolic phenotype in polycystic ovary syndrome
    Minooee, Sonia
    Ramezani Tehrani, Fahimeh
    Tohidi, Maryam
    Azizi, Fereidoun
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2017, 137 (02) : 110 - 115
  • [4] Metabolic syndrome and metabolic risk profile according to polycystic ovary syndrome phenotype
    Bil, Enes
    Dilbaz, Berna
    Cirik, Derya Akdag
    Ozelci, Runa
    Ozkaya, Enis
    Dilbaz, Serdar
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2016, 42 (07) : 837 - 843
  • [5] SPEXIN AS A NEW METABOLIC BIOMARKER IN WOMEN WITH POLYCYSTIC OVARY SYNDROME.
    Ilhan, G. Anik
    Yildizhan, B.
    FERTILITY AND STERILITY, 2018, 110 (04) : E118 - E118
  • [6] Metabolic syndrome in adolescents with polycystic ovary syndrome
    Vrbikova, Jana
    Zamrazilova, Hana
    Sedlackova, Barbora
    Sanajderova, Marta
    GYNECOLOGICAL ENDOCRINOLOGY, 2011, 27 (10) : 820 - 822
  • [7] Is Apelin a New Biomarker in Patients With Polycystic Ovary Syndrome?
    Dravecka, Ingrid
    Figurova, Jana
    Lazurova, Ivica
    PHYSIOLOGICAL RESEARCH, 2021, 70 : S635 - S641
  • [8] Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome
    Lerchbaum, Elisabeth
    Schwetz, Verena
    Giuliani, Albrecht
    Pieber, Thomas R.
    Obermayer-Pietsch, Barbara
    FERTILITY AND STERILITY, 2012, 98 (05) : 1318 - +
  • [9] Nephrolithiasis and Polycystic Ovary Syndrome: A Case-Control Study Evaluating Testosterone and Urinary Stone Metabolic Panels
    Fedrigon, Donald, III
    Alazem, Kareem
    Sivalingam, Sri
    Monga, Manoj
    Calle, Juan
    ADVANCES IN UROLOGY, 2019, 2019
  • [10] Metabolic syndrome and polycystic ovary syndrome
    Sobstyl, Malgorzata
    Tkaczuk-Wlach, Joanna
    Sobstyl, Jacek
    Jakiel, Grzegorz
    PRZEGLAD MENOPAUZALNY, 2011, 10 (01): : 74 - 78